TD2 Translational Drug Development CEO and leadership

Dr. Gately is the President and CEO of Translational Drug Development (TD2). Prior to joining TD2, an adjunct Assistant Professor of Medicine at the Northwestern University Feinberg School of Medicine. Prior to joining TD2, Dr. Gately served as a consultant to Takeda Pharmaceuticals North America, Medical and Scientific Affairs group where he was responsible for the integration of research and regulatory data on portfolio compounds for commercial planning. He was also involved in the scientific due diligence for oncology business development opportunities.

Prior to that, he served as Executive Director of Translational Medicine at NeoPharm and was in charge of the design and implementation of research to enhance the understanding of existing products and development candidates for optimal positioning.

Prior to joining NeoPharm, Dr. Gately was a Research Assistant Professor at Northwestern University where he focused on developing pharmacologic and endogenous inhibitors of angiogenesis. During this time, he served as a consultant to the Oncology Clinical Research team at Searle/Monsanto (now Pfizer) and was responsible for scientific input on clinical trial designs to rapidly assess the utility of antiangiogenic compounds.

Dr. Gately obtained his Ph.D. from McGill University in the Department of Neurology and Neurosurgery at the Montreal Neurological Institute and Hospital.

Dr. Von Hoff is currently Physician in Chief and Director of Translational Research at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is also Chief Scientific Officer for US Oncology and for HonorHealth’s Clinical Research Institute. He is also a Clinical Professor of Medicine at, University of Arizona.

Dr. Von Hoff graduated from Carroll College and received his medical degree from Columbia University College of Physicians and Surgeons. He went on to complete his internship and residency in internal medicine at the University of California, San Francisco, and a fellowship in medical oncology at the National Cancer Institute. Von Hoff became a professor in the departments of medicine and cellular and structural biology at the University of Texas Health Science Center, San Antonio. In 1989, he became the founding director of the Institute for Drug Development at the Cancer Therapy and Research Center in San Antonio and 10 years later he became the director of the cancer center and professor of medicine at the University of Arizona.

Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved at the beginning of the development of many of the agents now use routinely, including mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, and others. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies for patients with pancreatic and other advanced cancers.

Dr. Von Hoff has published more than 648 papers, 138 book chapters, and over 1085 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care.

TARA FRANKS is the Chief Operating Officer at Translational Drug Development. Tara attended Arizona State University.